MYDA Advisors LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

MYDA Advisors LLC boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 37.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,000 shares of the biopharmaceutical company's stock after buying an additional 15,000 shares during the period. MYDA Advisors LLC's holdings in TG Therapeutics were worth $1,656,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in TGTX. HighTower Advisors LLC raised its holdings in shares of TG Therapeutics by 19.6% in the 3rd quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company's stock valued at $294,000 after buying an additional 2,053 shares during the period. Barclays PLC increased its stake in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. Synovus Financial Corp acquired a new stake in shares of TG Therapeutics during the third quarter worth about $465,000. Franklin Resources Inc. boosted its stake in shares of TG Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock valued at $2,945,000 after purchasing an additional 4,756 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on TGTX. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Up 1.3 %

TGTX stock traded up $0.54 during trading on Friday, hitting $40.84. 776,739 shares of the company's stock were exchanged, compared to its average volume of 3,085,631. The stock has a market capitalization of $6.48 billion, a price-to-earnings ratio of -409.59 and a beta of 2.14. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The business has a 50-day moving average price of $36.98 and a two-hundred day moving average price of $32.31.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.